0001104659-24-037880.txt : 20240322 0001104659-24-037880.hdr.sgml : 20240322 20240322161608 ACCESSION NUMBER: 0001104659-24-037880 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240320 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Jennifer Kayden CENTRAL INDEX KEY: 0001801372 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 24775444 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Chien Jennifer DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm249484-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-20 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001801372 Lee Jennifer Kayden C/O RHYTHM PHARMACEUTICALS, INC. 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 EVP, Head of North America 0 Common Stock 2024-03-20 4 S 0 9169 38.22 D 15918 D Common Stock 2024-03-20 4 S 0 9066 39.33 D 6852 D The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $37.75 to $38.68. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $38.75 to $39.72. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Hunter Smith, Attorney-in-Fact for Jennifer Kayden Lee 2024-03-22